Ildong’s ‘Besivo’ shows equivalence and improved safety to Viread

Published: 2017-05-25 16:25:00
Updated: 2017-05-25 16:24:52

“Besivo, a chronic hepatitis B treatment, is a product which proved equivalent efficacy and improved safety to Viread.”

Ildong Pharmaceutical held a press conference for ‘Besivo Tab,’ a new chronic hepatitis B treatment which recently acquired commercialization approval, with the subject ‘New Ch...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean




Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.